MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Kodu・Aktsiate loetelu・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Suletud

1.16 6.42

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.04

Max

1.18

Põhinäitajad
By Trading Economics
Sissetulek	-809K -5.9M
Müük	90K 90K
Kasumimarginaal	-6,600
Töötajad	25
EBITDA	2.6M -4.9M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+496.33% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-11M 31M
Eelmine avamishind	-5.26
Eelmine sulgemishind	1.16

Actinium Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2026, 17:26 UTC

Uudisväärsed sündmused

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. apr 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Market Talk Roundup: Latest on U.S. Politics

7. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. apr 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:15 UTC

Market Talk

Uudisväärsed sündmused

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. apr 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. apr 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. apr 2026, 23:01 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. apr 2026, 22:58 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

7. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. apr 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. apr 2026, 19:17 UTC

Uudisväärsed sündmused

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. apr 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. apr 2026, 18:41 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. apr 2026, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. apr 2026, 18:39 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. apr 2026, 18:24 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. apr 2026, 16:21 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Actinium Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

496.33% tõus

12 kuu keskmine prognoos

Keskmine 6.5 USD 496.33%

Kõrge 9 USD

Madal 4 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Actinium Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Actinium Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.